SWM
VKTX icon

SeaCrest Wealth Management’s Viking Therapeutics VKTX Stock Holding History

SeaCrest Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,400
Closed -$258K – 697
2024
Q4 		$258K Sell
6,400
-790
-11% -$45K 0.03% 537
2024
Q3 		$455K Buy
7,190
+581
+9% +$34.1K 0.05% 367
2024
Q2 		$350K Sell
6,609
-1,800
-21% -$118K 0.04% 414
2024
Q1 		$690K Buy
+8,409
New +$374K 0.08% 248

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SeaCrest Wealth Management's VKTX Position: Q1 2025 in Review

SeaCrest Wealth Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 6,400 shares — an estimated $258K sold.

SeaCrest Wealth Management first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $690K in Q1 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • SeaCrest Wealth Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SeaCrest Wealth Management sold 6,400 Viking Therapeutics shares in Q1 2025, an estimated $258K.
  • SeaCrest Wealth Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • SeaCrest Wealth Management's Viking Therapeutics position peaked at $690K in Q1 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on SeaCrest Wealth Management's 13F filing for Q1 2025, filed 11 Apr 2025.